Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
selenium-containing alpha-D-1,6-glucan
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Selenium-containing alpha-D-1,6-glucan (Se-CPA) is a selenium-modified polysaccharide derived from the Chinese chestnut (*Castanea mollissima* Blume). It is currently being investigated as a preclinical research compound for its neuroprotective and anti-inflammatory properties. In animal models of Alzheimer's disease (APP/PS1 mice), Se-CPA has demonstrated the ability to improve cognitive function and depressive-like behavior by reducing oxidative stress, lowering serum lipopolysaccharide (LPS) levels, and inhibiting the activation of the NLRP3 inflammasome in astrocytes and microglia. Additionally, it has shown potential in remodeling the gut microbiome, increasing microbial diversity, and promoting the production of short-chain fatty acids (SCFAs). Beyond neurodegeneration, the compound has also been studied for its therapeutic effects in models of inflammatory bowel disease, such as DSS-induced colitis, where it acts to remodel dysbacteriosis and reduce systemic inflammation.
- Other names
- selenylation alpha-D-1,6-glucanselenium-containing α-D-1,6-glucan
02
Targets
NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)
Beyond the preview
Go deeper on selenium-containing alpha-D-1,6-glucan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on selenium-containing alpha-D-1,6-glucan.